Search results
Showing 1 to 15 of 129 results for epilepsy
All NICE products on epilepsy. Includes any guidance, advice and quality standards.
This guideline covers diagnosing and managing epilepsy in children, young people and adults in primary and secondary care, and referral to tertiary services. It aims to improve diagnosis and treatment for different seizure types and epilepsy syndromes, and reduce the risks for people with epilepsy.
Show all sections
Sections for NG217
- Overview
- 1 Diagnosis and assessment of epilepsy
- 2 Information and support
- 3 Referral to tertiary specialist services
- 4 Principles of treatment, safety, monitoring and withdrawal
- 5 Treating epileptic seizures in children, young people and adults
- 6 Treating childhood-onset epilepsies
- 7 Treating status epilepticus, repeated or cluster seizures, and prolonged seizures
This quality standard covers diagnosing and managing epilepsies in children, young people and adults. It describes high-quality care in priority areas for improvement.
View quality statements for QS211Show all sections
Sections for QS211
- Quality statements
- Quality statement 1: Referral and assessment after first seizure
- Quality statement 2: Referral to tertiary specialist services
- Quality statement 3: Epilepsy specialist nurse
- Quality statement 4: Epilepsy care plan
- Quality statement 5: Mental health and wellbeing
- Quality statement 6: Neurodevelopment and learning disabilities
- Update information
Cenobamate for treating focal onset seizures in epilepsy (TA753)
Evidence-based recommendations on cenobamate (Ontozry) for treating focal onset seizures with or without secondary generalised seizures in adults with drug-resistant epilepsy that has not been adequately controlled with at least 2 antiseizure medicines.
This guideline covers prescribing of cannabis-based medicinal products for people with intractable nausea and vomiting, chronic pain, spasticity and severe treatment-resistant epilepsy.
Transient loss of consciousness ('blackouts') in over 16s (CG109)
This guideline covers assessment, diagnosis and referral for people over 16 who have had a transient loss of consciousness (TLoC; also called a blackout). It aims to improve care for people with TLoC by specifying the most effective assessments and recommending when to refer to a specialist.
Suspected neurological conditions: recognition and referral (NG127)
This guideline covers the initial assessment of symptoms and signs that might indicate a neurological condition. It helps non-specialist healthcare professionals to identify people who should be offered referral for specialist investigation.
Show all sections
NICE has developed a medtech innovation briefing (MIB) on 24/7 EEG SubQ for epilepsy .
Awaiting development [GID-TA10519] Expected publication date: TBC
Deep brain stimulation for refractory epilepsy in adults (IPG678)
Evidence-based recommendations on deep brain stimulation for refractory epilepsy in adults. This involves implanting an electrical stimulator in the brain.
View recommendations for IPG678Show all sections
MRI-guided laser interstitial thermal therapy for drug-resistant epilepsy (IPG671)
Evidence-based recommendations on MRI-guided laser interstitial thermal therapy for drug-resistant epilepsy in adults and children. This involves inserting a laser into the area of the brain causing seizures.
View recommendations for IPG671Show all sections
Vagus nerve stimulation for refractory epilepsy in children (IPG50)
Evidence-based recommendations on vagus nerve stimulation for refractory epilepsy in children. This involves placing a device under the skin to send a burst of nerve messages through the nerve.
View recommendations for IPG50Show all sections
Sections for IPG50
NICE indicators. NM209 epilepsy guidance.
NICE's impact on managing long-term conditions in children in the community
Cerebral palsy in under 25s: assessment and management (NG62)
This guideline covers diagnosing, assessing and managing cerebral palsy in children and young people from birth up to their 25th birthday. It aims to make sure they get the care and treatment they need for the developmental and clinical comorbidities associated with cerebral palsy, so that they can be as active and independent as possible.